Thanks Telepanel for your efforts. I made zero effort to contact IR myself, so it was unfair of me to phrase my post like I did. Because of corona leading to virtual conferences and many presentation cancellations (not just Resverlogix), I didn't blink at all when you relayed your prior info. I am very happy that things turned around. Now, hopefully we hear a more comprehensive CKD sub-study presentation that includes not just the MACE data, but also changes over time (multiple time points in protocol) for renal function (eGFR), alkaline phosphatase, and other related urinary/blood measurements (i.e. albumin, creatinine, hsCRP) that would complete the story and that were already pre-planned.

https://www.resverlogix.com/upload/media_element/125/20402f6425eb/2018-05-02-era-edta-poster-2018-kidney-disease-subgroup.pdf

BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60.